DNA Extraction Reagents Supply for Newborn Screening

The contract entails the supply of QuantaBio Part #95171-500 LIFSCIELT EXTRACTA DBS 500ML reagents specifically for use in SCID-SMA newborn screening testing within the Texas Newborn Screening Program. The reagents must be manufactured and shipped as a single annual lot to ensure consistency, traceability, and compatibility with the program’s diagnostic protocols. This requirement underscores the need for precise batch control and reliability in reagent performance, as any variability could impact screening accuracy and infant health outcomes. The reagents are critical to the program’s ability to promptly and accurately identify life-threatening metabolic and genetic conditions in newborns. The contract is classified as a subcontract under NAICS code 325412, indicating it involves the manufacturing of chemical products for medical diagnostics. It is issued by the Texas Department of State Health Services with a posted date of July 1, 2026, and a response deadline of July 15, 2026. Performance is expected to occur within Texas, aligning with state-specific public health initiatives. Although no set-aside provisions or point of contact details are provided, the solicitation is accessible via the Texas SmartBuy portal, and suppliers must meet stringent quality and logistical standards to qualify for award. Timely delivery of the single annual lot is essential to avoid disruptions in the state’s newborn screening schedule.